The Swedish Medical Products Agency (MPA) has given a positive opinion for Allergan’s Belkyra (deoxycholic acid), a drug to treat double chin or moderate to severe convexity or fullness associated with submental fat \ in adults when the presence of submental fat has a psychological impact for the patient. Belkyra is being evaluated through the decentralized procedure, with the Swedish MPA acting as the reference member state for 20 other countries in the European Union, as well as Iceland and Norway.

As a next step, Allergan will work to secure the national marketing authorizations in the concerned member states. Once the national licenses have been granted, Allergan will begin to train healthcare professional customers on the safe and effective use of this new treatment. Belkyra is already licensed in Canada, as well as in the US as Kybella.

Allergan gained Kybella through its $2.1 billion acquisition of Kythera in 2015.

Source: Allergan